75. Cushing disease Clinical trials / Disease details

Clinical trials : 205 / Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03145285 (ClinicalTrials.gov)	April 18, 2017	26/4/2017	Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma	Cushing Syndrome;Adrenocortical Carcinoma	Drug: Abiraterone Acetate	Azienda Ospedaliera Spedali Civili di Brescia	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga Hospital	Active, not recruiting	18 Years	N/A	All	10	Phase 2	Italy
2	EUCTR2016-000945-29-IT (EUCTR)	16/06/2016	04/11/2020	Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS)	Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS	Cushing’s syndrome in patients with adrenocortical carcinoma MedDRA version: 20.0;Level: PT;Classification code 10001388;Term: Adrenocortical carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]	Trade Name: ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE Product Name: ZYTIGA Product Code: [ZYTIGA] INN or Proposed INN: abiraterone acetato	AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Italy